Other possible serious side effects include inflammation of the pancreas, low blood sugar, allergic reactions, kidney problems, gallbladder issues, stomach paralysis, thyroid tumors, or cancer.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

Medications like Ozempic and Wegovy are famous for their weight loss benefits, but some scientists want to know more about how these drugs impact muscle loss. In a new commentary for The Lancet, an ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.

On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...

Novo Nordisk has raised alarm about safety concerns related to compounded versions of its semaglutide-based drugs, Wegovy and Ozempic. The pharmaceuticals giant acknowledged reports of 10 deaths and ...